Briefly describe neuropathic pain. Diagnosis and management of trigeminal neuralgia 20 mark answer

Reading File

Finding Sources

Reading File

Searching PubMed

trigeminal neuralgia treatment

Searching the Web

trigeminal neuralgia diagnosis management guideline 2024

Neuropathic Pain: Brief Description

Neuropathic pain is pain arising from a lesion or disease affecting the somatosensory nervous system (peripheral nerves, dorsal root ganglion, spinal cord, or brain), rather than from ongoing tissue damage detected by normal nociceptors. Examples include diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, and central post-stroke pain.

Key features:

Quality: burning, tingling, shooting, or electric shock-like
May be spontaneous (no stimulus) or triggered by very light touch
Allodynia - pain from normally non-painful stimuli (e.g., light touch)
Hyperpathia/hyperalgesia - exaggerated pain response to mild painful stimuli
Sensory deficit often co-exists in the same distribution as the pain
Often resistant to standard analgesics (NSAIDs, opioids less reliably effective)

Mechanism: Nerve injury increases sodium channel density in damaged afferents, causing spontaneous ectopic firing and mechanical hypersensitivity. Deafferented central pain-transmission neurons (spinal cord/thalamus) can also become spontaneously hyperactive. Damaged nociceptors may also acquire adrenergic sensitivity, underlying sympathetically maintained pain seen in complex regional pain syndrome (Harrison's Principles of Internal Medicine, 22e).

Trigeminal Neuralgia

Definition

Trigeminal neuralgia (TN) is a form of neuropathic facial pain characterized by paroxysmal, unilateral pain within the distribution of one or more divisions of the trigeminal nerve (CN V), most commonly the maxillary (V2) and mandibular (V3) divisions.

Clinical Features

Pain is described as electric shock-like, shooting, or lancinating
Each paroxysm lasts seconds, but attacks can recur in rapid succession, blurring into a cluster; a dull residual ache may follow
Triggered by innocuous stimuli in a trigger zone (often near the nasolabial fold): chewing, talking, tooth-brushing, cold wind on the face
Pain confined to the ophthalmic (V1) division alone is rare
Attacks during sleep are uncommon
Frequent attacks can lead to weight loss, dehydration, and depression
Runs a remitting-relapsing course: exacerbations for weeks to months followed by spontaneous remissions of months to years

Classification (ICHD-3)

Classical TN - vascular compression of the trigeminal nerve root confirmed on MRI or at surgery, with nerve root atrophy/displacement
Secondary TN - due to an underlying lesion (e.g., multiple sclerosis, posterior fossa tumor); may have background continuous pain in addition to paroxysms
Idiopathic TN - no identifiable cause or morphological nerve change found

Etiology/Pathogenesis

Most classical cases result from neurovascular compression of the trigeminal nerve root entry zone (commonly by the superior cerebellar artery, AICA/PICA, or superior petrosal vein), causing focal demyelination and hyperexcitability with ectopic, repetitive discharges. Onset is typically after age 40 (90% of cases), slightly more common in women; incidence rises with age.

Diagnosis

Diagnosis is primarily clinical, based on history of the characteristic paroxysmal pain pattern and trigger zones.

Physical examination
- Classical/idiopathic TN: normal neurological exam, no sensory loss, motor (masticatory) function intact
- Sensory loss or masseter weakness suggests a secondary cause (trigeminal neuropathy) - warrants search for a mass lesion affecting the ganglion, sensory root, or root entry zone
Laboratory/electrophysiology
- Normal in idiopathic TN; EMG and blink reflex studies are unremarkable
Imaging
- MRI brain (with trigeminal-nerve-specific sequences) is essential in all patients to exclude secondary causes: pontine infarct, demyelinating plaque (MS), meningioma, schwannoma, or skull-base malignancy
- High-resolution MRI/MRA can identify neurovascular compression in classical TN
Differential diagnosis: dental pathology, temporomandibular joint dysfunction, trigeminal autonomic cephalalgias (e.g., SUNCT), atypical facial pain, glossopharyngeal neuralgia, postherpetic neuralgia

Management

A. Medical (first-line)

Carbamazepine or oxcarbazepine (sodium channel blockers) are the drugs of choice, with favorable response in most patients
- Carbamazepine: start 50-100 mg, titrate slowly; maintenance 600-1200 mg/day in divided doses
- Side effects: sedation, ataxia, vertigo; monitor CBC (agranulocytosis), LFTs, and serum sodium (hyponatremia, more common with oxcarbazepine)
- Once pain-free, taper periodically to check for remission

B. Second-line drugs

Used alone or in combination when first-line agents fail or are not tolerated:

Gabapentin, pregabalin, phenytoin, baclofen
Others: lamotrigine, valproate, clonazepam, topiramate
Gabapentin is a reasonable initial alternative given its benign side-effect profile

C. Acute severe exacerbation

IV fosphenytoin 15-20 mg PE/kg
Topical ophthalmic anesthetic (proparacaine) to the ipsilateral conjunctival sac for temporary relief

D. Surgical/interventional (for medically refractory disease)

Choice depends on patient age, comorbidities, and recurrence-risk tolerance:

Procedure	Notes
Peripheral alcohol nerve block	Simple, low morbidity, but relapse common in 6-18 months
Percutaneous radiofrequency thermocoagulation of gasserian ganglion	Pain relief up to 93%; preferred in elderly/comorbid patients; risk of corneal anesthesia (V1), dysesthesia
Percutaneous balloon compression	Technically simple; higher early recurrence (2-3 years)
Stereotactic Gamma Knife radiosurgery	Minimally invasive; relatively high recurrence; risk of dysesthesia especially after prior surgery
Microvascular decompression (MVD)	Craniotomy to separate the offending vessel from the nerve root; best long-term relief (~70% excellent relief at 10 years, Jannetta series), preserves facial sensation; procedure of choice in young, fit patients; risks include ~1% mortality and injury to CN IV/VII/VIII

Lesions causing secondary TN (e.g., compressive mass) require surgical decompression/removal of the causative lesion.
Treatment must be individualized: young/fit patients favor MVD; elderly/comorbid patients favor peripheral/percutaneous ganglion procedures.

(Source: Bradley and Daroff's Neurology in Clinical Practice, p. 2498-2499; Harrison's Principles of Internal Medicine, 22e)

Recent Evidence (supplementary check)

A 2024 meta-analysis confirms carbamazepine's efficacy and safety profile in TN (PMID: 38872538), and a 2024 systematic review/meta-analysis found minimally invasive procedures (radiofrequency ablation, rhizotomy, radiosurgery) are effective options particularly in MS-related secondary TN (PMID: 38648730), consistent with the textbook guidance above. The European Academy of Neurology has also updated its TN management guideline with refined imaging criteria and updated pharmacological/surgical recommendations (Ashina et al., Nat Rev Dis Primers 2024, PMID 38816415) - worth reviewing for exam purposes if more granular guideline detail is needed.

This is a shared conversation. Sign in to Orris to start your own chat.